Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-22-000085
Filing Date
2022-11-07
Accepted
2022-11-07 08:38:37
Documents
6
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 6-K q32022form6-k.htm 6-K 24885
2 EX-99.1 2022 THIRD QUARTER INTERIM FINANCIAL STATEMENTS ex991-interimfsseptember30.htm EX-99.1 377829
3 EX-99.2 2022 THIRD QUARTER MD&A ex992-q32022mda.htm EX-99.2 211392
4 EX-99.3 Q3 2022 CERTIFICATION CEO ex993-q32022certificationx.htm EX-99.3 14760
5 EX-99.4 Q3 2022 CERTIFICATION CFO ex994-q32022certificationx.htm EX-99.4 14657
6 oncolyticslogotaglinebluea.jpg GRAPHIC 355294
  Complete submission text file 0001129928-22-000085.txt   1083939
Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 221363875
SIC: 2834 Pharmaceutical Preparations